3-(2-amino-1,3-benzoxazol-5-yl)-1-[(3-methylthietan-3-yl)methyl]pyrazolo[3,4-d]pyrimidine-4,6-diamine

ID: ALA5220948

PubChem CID: 142608591

Max Phase: Preclinical

Molecular Formula: C17H18N8OS

Molecular Weight: 382.45

Names and Identifiers

Canonical SMILES:  CC1(Cn2nc(-c3ccc4oc(N)nc4c3)c3c(N)nc(N)nc32)CSC1

Standard InChI:  InChI=1S/C17H18N8OS/c1-17(6-27-7-17)5-25-14-11(13(18)22-15(19)23-14)12(24-25)8-2-3-10-9(4-8)21-16(20)26-10/h2-4H,5-7H2,1H3,(H2,20,21)(H4,18,19,22,23)

Standard InChI Key:  YTOAJUIMCNAYNE-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 31  0  0  0  0  0  0  0  0999 V2000
   -1.3514    0.0316    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3369    0.8565    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6443   -0.3932    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1447   -0.1521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4133    0.6279    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2232    0.7852    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4918    1.5653    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2513    1.8876    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.1794    2.7094    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8021    3.2507    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3756    2.8951    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.9506    2.1879    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1408    2.0306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1278    1.2505    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6178   -0.8279    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.1213   -1.4868    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3624   -2.2758    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1663   -2.4614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6587   -1.2181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3803   -1.6181    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0875   -1.1931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0730   -0.3682    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8021   -1.6057    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4075   -3.2507    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1663   -1.6221    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9917   -1.6221    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    1.9917   -2.4614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  1  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  9  8  2  0
  9 10  1  0
 11  9  1  0
 12 11  1  0
  7 12  1  0
 12 13  2  0
 13 14  1  0
 14  5  2  0
  4 15  2  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 19 16  1  0
  3 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22  1  2  0
 21 23  1  0
 18 24  1  0
 25 18  1  0
 26 25  1  0
 26 27  1  0
 18 27  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5220948

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 382.45

Molecular Weight (Monoisotopic): 382.1324

AlogP: 2.13

#Rotatable Bonds: 3

Polar Surface Area: 147.69

Molecular Species: NEUTRAL

HBA: 10

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.86

CX Basic pKa: 5.77

CX LogP: 1.83

CX LogD: 1.82

Aromatic Rings: 4

Heavy Atoms: 27

QED Weighted: 0.48

Np Likeness Score: -0.86

References

1. Oleksak P, Nepovimova E, Chrienova Z, Musilek K, Patocka J, Kuca K..  (2022)  Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).,  238  [PMID:35688004] [10.1016/j.ejmech.2022.114498]

Source

Source(1):

• Scientific Literature